AR023261A1 - EMPLOYMENT OF ARILALCANOILPIRIDAZINAS - Google Patents

EMPLOYMENT OF ARILALCANOILPIRIDAZINAS

Info

Publication number
AR023261A1
AR023261A1 ARP000101547A ARP000101547A AR023261A1 AR 023261 A1 AR023261 A1 AR 023261A1 AR P000101547 A ARP000101547 A AR P000101547A AR P000101547 A ARP000101547 A AR P000101547A AR 023261 A1 AR023261 A1 AR 023261A1
Authority
AR
Argentina
Prior art keywords
hal
independently represent
atoms
substituted
represent
Prior art date
Application number
ARP000101547A
Other languages
Spanish (es)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR023261A1 publication Critical patent/AR023261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El empleo de las arilalcanoilpiridazinas de formula (1), en donde B representa A, OA, NH2, NHA, NAAo un heterociclo aromático con 1 a 4 átomos de N,O y/o S, el cual puede no estar sustituido o estar mono, di o trisustituido con Hal, A y/o OA; Q estáausente o representa alquileno C1-6; R1, R2 representanindependientemente -OH, OR5, -S-R5, -SO-R5, -SO2-R5, Hal, -NO2, -NH2, -NHR5 o -NR5R6; R1 y R2 juntos, también representan -O-CH2-O-; R5 y R6 representanindependientemente A, cicloalquilo C3-7,me tilencicloalquilo C4-8 o alquenilo C2-8; A, A representan independientemente alquilo C1-10, que puede estarsustituido con 1 a 5 átomos de F y/o Cl, y Hal representa F, Cl, Br o I; y/o de sus sales aceptables desde el punto de vista fisiologico,para prepararun medicamento destinado al tratamiento de la osteoporosis, los tumores, la aterosclerosis, la artritis reumatoidea, la esclerosis multiple, ladiabetes mellitus, la colitis ulcerativa y el SIDA. Estos compuestos inhiben selectivamentela fosf odiesterasa IV.The use of the arylalcanoylpyridazines of formula (1), wherein B represents A, OA, NH2, NHA, NAA or an aromatic heterocycle with 1 to 4 atoms of N, O and / or S, which may not be substituted or be mono , di or trisubstituted with Hal, A and / or OA; Q is absent or represents C1-6 alkylene; R1, R2 independently represent -OH, OR5, -S-R5, -SO-R5, -SO2-R5, Hal, -NO2, -NH2, -NHR5 or -NR5R6; R1 and R2 together also represent -O-CH2-O-; R5 and R6 independently represent A, C3-7 cycloalkyl, C4-8 tilecycloalkyl or C2-8 alkenyl; A, A independently represent C1-10 alkyl, which may be substituted with 1 to 5 atoms of F and / or Cl, and Hal represents F, Cl, Br or I; and / or its physiologically acceptable salts, to prepare a medicament for the treatment of osteoporosis, tumors, atherosclerosis, rheumatoid arthritis, multiple sclerosis, ladiabetes mellitus, ulcerative colitis and AIDS. These compounds selectively inhibit phosphodiesterose IV.

ARP000101547A 1999-04-06 2000-04-05 EMPLOYMENT OF ARILALCANOILPIRIDAZINAS AR023261A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19915364A DE19915364A1 (en) 1999-04-06 1999-04-06 Use of arylalkanoylpyridazines

Publications (1)

Publication Number Publication Date
AR023261A1 true AR023261A1 (en) 2002-09-04

Family

ID=7903583

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101547A AR023261A1 (en) 1999-04-06 2000-04-05 EMPLOYMENT OF ARILALCANOILPIRIDAZINAS

Country Status (18)

Country Link
EP (1) EP1143944A3 (en)
JP (1) JP2002541095A (en)
KR (1) KR20020000550A (en)
CN (1) CN1355702A (en)
AR (1) AR023261A1 (en)
AU (1) AU3811600A (en)
BR (1) BR0009549A (en)
CA (1) CA2367051A1 (en)
CZ (1) CZ20013598A3 (en)
DE (1) DE19915364A1 (en)
HU (1) HUP0200311A3 (en)
ID (1) ID30381A (en)
MX (1) MXPA01010034A (en)
NO (1) NO20014845L (en)
PL (1) PL350963A1 (en)
RU (1) RU2001129703A (en)
WO (1) WO2000059484A2 (en)
ZA (1) ZA200109120B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096322A1 (en) * 2002-03-01 2005-05-05 Susumu Igarashi Nitrogen-containing heterocyclic compound
DE10224888A1 (en) * 2002-06-05 2003-12-24 Merck Patent Gmbh pyridazine
DE10225574A1 (en) * 2002-06-10 2003-12-18 Merck Patent Gmbh New 1-acyl-3-phenyl-5,6-dihydro-4H-pyridazine derivatives, are phosphodiesterase IV inhibitors useful e.g. for treating asthma, allergy, inflammation, autoimmune diseases or myocardial diseases
US20060173009A1 (en) * 2003-01-07 2006-08-03 Hiroyuki Kanoh Agent inducing increase in bone mass
AR067354A1 (en) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc USEFUL COMPOUNDS AS INHIBITORS OF RAF QUINASA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (en) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazines
DE19826841A1 (en) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazines
DE19850701A1 (en) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoyl pyridazines
DE19915365A1 (en) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazine derivatives

Also Published As

Publication number Publication date
ID30381A (en) 2001-11-29
BR0009549A (en) 2002-03-26
NO20014845D0 (en) 2001-10-05
NO20014845L (en) 2001-10-05
EP1143944A3 (en) 2002-09-11
HUP0200311A2 (en) 2002-11-28
CZ20013598A3 (en) 2002-01-16
JP2002541095A (en) 2002-12-03
ZA200109120B (en) 2003-11-13
MXPA01010034A (en) 2002-04-24
WO2000059484A3 (en) 2001-08-23
CA2367051A1 (en) 2000-10-12
EP1143944A2 (en) 2001-10-17
RU2001129703A (en) 2004-02-20
DE19915364A1 (en) 2000-10-12
KR20020000550A (en) 2002-01-05
PL350963A1 (en) 2003-02-24
AU3811600A (en) 2000-10-23
WO2000059484A2 (en) 2000-10-12
CN1355702A (en) 2002-06-26
HUP0200311A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
NO2022019I1 (en) Eribulin or a pharmaceutically acceptable salt thereof - extended SPC
UY26727A1 (en) USEFUL TROPANIC DERIVATIVES IN THERAPY
AR038136A1 (en) CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
ES2485867T3 (en) Opioid Carboxamide Compounds
PE20050130A1 (en) ORGANIC COMPOUNDS
AR040773A1 (en) USEFUL PIRAZOLS AS INHIBITORS OF GSK-3
CY1110355T1 (en) Activator of subunit multiplexer subunit activator D
ATE506354T1 (en) SUBSTITUTED ARYLCYCLOPROPYLACETAMIDE AS GLUCOCINASE ACTIVATORS
CO5540309A2 (en) DERIVATIVES OF 4- (FENIL-PIPERAZINIL-METIL) BENZAMIDA AND ITS USES FOR THE TREATMENT OF PAIN, ANXIETY OR GASTROINTESTINAL DISORDERS
FI940105A0 (en) Processes for the preparation of sertraline intermediates
ES2184280T3 (en) INDOL COMPOUNDS AS COX-2 'INHIBITORS.
UY29070A1 (en) FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES
AR083017A1 (en) ESTER PRODUCTIONS OF [3- (1- (1H-IMIDAZOL-4-IL) ETIL) -2-METHYLPHENYL] METHANOL
AR040629A1 (en) HYDRAZON-MALONITRILE DERIVATIVES, THE MEDICINES THAT CONTAIN THEM, USE FOR THE PREPARATION OF A MEDICINAL PRODUCT, A SET OF ELEMENTS (KIT) THAT UNDERSTAND THEM, A PROCEDURE FOR THE PREPARATION, THE USEFUL INTERMEDIARIES IN THIS PROCEDURE, AND A PROCEDURE SAID DERIVATIVES
AR023261A1 (en) EMPLOYMENT OF ARILALCANOILPIRIDAZINAS
AR021068A1 (en) BENZOILPIRIDAZINAS AND PROCEDURES TO PREPARE THEM; PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCEDURE TO PREPARE THEM, AND USE OF DICHASBENZOILPIRIDAZINAS
FI851996L (en) NEW SUBSTITUTES BIS- (4-AMINOPHENYL) -SULPHONER, DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING SAOSOM LAEKEMEDEL.
AR053989A1 (en) ESPIRO-HYDANTOINE COMPOUNDS REPLACED WITH PIRIDILE. PHARMACEUTICAL COMPOSITIONS AND OBTAINING PROCESSES.
AR019867A1 (en) USE OF A PIRROLIDINE DERIVATIVE FOR THE MANUFACTURE OF A REPELLENT AGAINST INSECTS, ACAROS AND TICKETS, SUCH COMPOUND, A COMPOSITION THAT LOCOMPRESSES, A PROCESS FOR THE PREPARATION OF SUCH COMPOSITION, AND A PROCESS TO REPELL INSECTS OF PLACES AND PLACES
PE20040533A1 (en) ESTERES IN POSITION 20 OF THE CAMPTOCINES
AR066404A1 (en) NON-NUCLEOSID INHIBITORS OF INVERSE TRANSCRIPT
DK0500409T3 (en) Derivatives of 4-pyrimidinols, their preparation and use in therapy
SE8303987L (en) N-PHENYLPYRAZOLD DERIVATIVES USED AS HERBICIDES
AR005549A1 (en) DERIVATIVES OF 1-PIRAZOL-3-ILETIL-4-INDOL-3-ILPIPERIDINA, A PROCEDURE FOR PREPARING THEM, MEDICINES AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, A PROCEDURE FOR PREPARING THE PHARMACEUTICAL PREPARATIONS AND USE OF THE SAME MEDICINAL PREPARATIONS FOR THE PREPARATIONS
AR045459A1 (en) REPLACED THIOPHENS AND USES OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure